UK's NICE Rejects GSK Breast Cancer Treatment
21 October
GlaxoSmithkline's Tyverb - in combination with capecitabine for the treatment of an aggressive form of advanced breast cancer - has been rejected by the UK's National Institute for Health and Clinical Excellence (NICE).
In rejecting the treatment for ErbB2-positive, NICE acknowledged that lapatinib met its end-of-life (EOL) criteria - offering a significant extension to life - but felt the drug was not a cost-effective use of National Health Service resources.
"NICE developed additional criteria specifically to help secure greater patient access to new treatments that offer precious extra time at the end of life. It is disappointing that, despite acknowledging Tyverb meets these criteria and GSK offering to bear the cost of lapatinib for up to 12 weeks, NICE is still proposing to reject lapatinib," commented Simon Jose, General Manager of GSK UK. He added: "We will continue to offer our patient access programme to individual NHS Trusts to ensure patients have access to Tyverb."
GSK reports that the NICE decision on the treatment will affect 2,000 women a year in the UK. By comparison, lapatinib is funded in 18 other European countries for the treatment of women whose advanced breast cancer has returned despite treatment with standard chemotherapy regimes.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.
